Press releases
Publication provides timely and critical reviews of important topics in medicinal chemistry
Read more
STORM Therapeutics’ will be attending the following virtual conferences.
Read more
STC-15, the first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies.
Read more
Presentations will showcase the activity of first-in-class METTL3 inhibitors in a range of solid tumours, building on prior POC data in AML. Establishes new therapeutic opportunities for METTL3 inhibitors across a wide range of solid cancers
Read more
Dr. Holz has over 25 years’ experience in pharmaceutical drug development in Europe and North America.
Read more